# HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

> **NCT07215468** · PHASE2 · RECRUITING · sponsor: **TaiMed Biologics Inc.** · enrollment: 75 (estimated)

## Conditions studied

- HIV -1 Infection

## Interventions

- **DRUG:** TMB-365
- **DRUG:** TMB-380
- **DRUG:** Baseline ART

## Key facts

- **NCT ID:** NCT07215468
- **Lead sponsor:** TaiMed Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215468, "HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07215468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*